In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Eurand: Oral Drug Delivery Solutions for Big Pharma Problems

Executive Summary

Focused on small-molecule oral drug delivery and with a proven technology for solubilizing compounds, Eurand believes it can win the lion's share of a growing market for rescuing insoluble development-stage candidates, while at the same time increasing its percentage of the drugs' profits.

You may also be interested in...



Investing Warburg Pincus Style

Warburg Pincus' favored health care business models eliminate as much time and risk as possible from the drug discovery and development process. Competition for such investments is increasing, but Warburg reckons its size, and experience, set it apart.

Innovating in the Industry's Backwaters: TransForm's Deals with Lilly and Alza

Too often, new discovery platforms brought in from biotechs have increased the risk and complexity of the R&D process. Drug companies have begun to recognize this and have been cutting back on their discovery dealmaking. Thus, at a time when many platform-based start-ups are having trouble interesting Big Pharma in dealmaking, it is notable that TransForm Pharmaceuticals has managed to announce two major deals this month, both of which explicitly address the issue of R&D risk.

The New Pharmaceutical Sciences

Now that several waves of novel discovery technologies have failed to deliver promised efficiencies, pharmaceutical sciences once dismissed as boring are attracting increasing numbers of admirers. Appreciation for the practical is easing the way not only for precedented disciplines such as drug formulation and delivery, but also for utterly new technologies that offer solutions to specific R&D problems. Start-ups today know they bear a high burden of proof. Some have been hunkering down to get evidence they hope will in time convince skeptics and increase the value of their offerings, while others are agreeing to demonstrate their worth via pilot programs. Emerging start-up models are enabled by two key factors: huge stockpiles of venture capital and an expanded audience of potential partners-namely, big biotech and specialty pharmaceutical firms that are relatively wealthy and hungry for products.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC031354

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel